WO1996015241A3 - A polynucleotide tuberculosis vaccine - Google Patents
A polynucleotide tuberculosis vaccine Download PDFInfo
- Publication number
- WO1996015241A3 WO1996015241A3 PCT/US1995/014899 US9514899W WO9615241A3 WO 1996015241 A3 WO1996015241 A3 WO 1996015241A3 US 9514899 W US9514899 W US 9514899W WO 9615241 A3 WO9615241 A3 WO 9615241A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- mice
- vaccinated mice
- response
- proteins
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 229960002109 tuberculosis vaccine Drugs 0.000 title 1
- 241000699670 Mus sp. Species 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000005867 T cell response Effects 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108010041986 DNA Vaccines Proteins 0.000 abstract 1
- 229940021995 DNA vaccine Drugs 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 abstract 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 210000004989 spleen cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT95939161T ATE296882T1 (en) | 1994-11-14 | 1995-11-13 | POLYNUCLEOTIDE VACCINE AGAINST TB |
DK95939161T DK0792358T3 (en) | 1994-11-14 | 1995-11-13 | Polynucleotide tuberculosis vaccine |
DE69534250T DE69534250T2 (en) | 1994-11-14 | 1995-11-13 | POLYNUCLEOTIDE VACCINE AGAINST TBC |
PL95320091A PL184839B1 (en) | 1994-11-14 | 1995-11-13 | Polynucleotidic vaccine against tuberculosis |
CZ19971451A CZ289383B6 (en) | 1994-11-14 | 1995-11-13 | Polynucleotide and polynucleotide tuberculosis vaccine |
CA 2205175 CA2205175C (en) | 1994-11-14 | 1995-11-13 | A polynucleotide tuberculosis vaccine |
JP51633096A JP3881014B2 (en) | 1994-11-14 | 1995-11-13 | Polynucleotide tuberculosis vaccine |
AU41102/96A AU715067B2 (en) | 1994-11-14 | 1995-11-13 | A polynucleotide tuberculosis vaccine |
SK597-97A SK283254B6 (en) | 1994-11-14 | 1995-11-13 | A polynucleotide tuberculosis vaccine |
NZ296477A NZ296477A (en) | 1994-11-14 | 1995-11-13 | Polynucleotides and tuberculosis vaccines |
EP95939161A EP0792358B1 (en) | 1994-11-14 | 1995-11-13 | A polynucleotide tuberculosis vaccine |
HU9701841A HU222369B1 (en) | 1994-11-14 | 1995-11-13 | A polynucleotide tuberculosis vaccine |
NO972196A NO972196L (en) | 1994-11-14 | 1997-05-13 | Polynucleotide vaccine for tuberculosis |
FI972034A FI972034A (en) | 1994-11-14 | 1997-05-13 | Polynucleotide tuberculosis vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US338,992 | 1994-11-14 | ||
US08/338,992 US5736524A (en) | 1994-11-14 | 1994-11-14 | Polynucleotide tuberculosis vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996015241A2 WO1996015241A2 (en) | 1996-05-23 |
WO1996015241A3 true WO1996015241A3 (en) | 1996-11-07 |
Family
ID=23326996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/014899 WO1996015241A2 (en) | 1994-11-14 | 1995-11-13 | A polynucleotide tuberculosis vaccine |
Country Status (23)
Country | Link |
---|---|
US (2) | US5736524A (en) |
EP (1) | EP0792358B1 (en) |
JP (1) | JP3881014B2 (en) |
KR (1) | KR970707281A (en) |
CN (1) | CN1171814A (en) |
AT (1) | ATE296882T1 (en) |
AU (1) | AU715067B2 (en) |
CZ (1) | CZ289383B6 (en) |
DE (1) | DE69534250T2 (en) |
DK (1) | DK0792358T3 (en) |
ES (1) | ES2242193T3 (en) |
FI (1) | FI972034A (en) |
HU (1) | HU222369B1 (en) |
IL (1) | IL115883A0 (en) |
MX (1) | MX9703606A (en) |
NO (1) | NO972196L (en) |
NZ (1) | NZ296477A (en) |
PL (1) | PL184839B1 (en) |
PT (1) | PT792358E (en) |
RU (1) | RU2186109C2 (en) |
SK (1) | SK283254B6 (en) |
WO (1) | WO1996015241A2 (en) |
ZA (1) | ZA959608B (en) |
Families Citing this family (314)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003040165A2 (en) | 2000-10-19 | 2003-05-15 | Epimmune Inc. | Hla class i and ii binding peptides and their uses |
FR2711670B1 (en) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Nucleotide vector, composition containing it and vaccine for immunization against hepatitis. |
US6995008B1 (en) * | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
FR2732895B1 (en) * | 1995-04-11 | 1997-05-16 | Pasteur Merieux Serums Vacc | USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTING AGENT, AS A VACCINE ADDITIVE, OR AS A MEDICINAL PRODUCT |
US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6338852B1 (en) | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6290969B1 (en) | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US20020165183A1 (en) * | 1999-11-29 | 2002-11-07 | Hans Herweijer | Methods for genetic immunization |
US20070021364A1 (en) * | 1995-12-13 | 2007-01-25 | Hans Herweijer | Methods for genetic immunization |
ZA973642B (en) * | 1996-04-26 | 1997-11-25 | Merck & Co Inc | DNA vaccine formulations. |
US5846946A (en) * | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
FR2751228B1 (en) * | 1996-07-19 | 1998-11-20 | Rhone Merieux | BOVINE POLYNUCLEOTIDE VACCINE FOR INTRADERMAL ROUTE |
FR2751225B1 (en) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | AVIAN POLYNUCLEOTIDE VACCINE FORMULA |
JP2001500738A (en) * | 1996-09-17 | 2001-01-23 | カイロン コーポレイション | Compositions and methods for treating intracellular diseases |
US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US20060002949A1 (en) * | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
WO1998035029A1 (en) * | 1997-02-07 | 1998-08-13 | Vanderbilt University | Synthetic genes for recombinant mycobacterium proteins |
US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US20040258703A1 (en) * | 1997-11-14 | 2004-12-23 | The Government Of The Us, As Represented By The Secretary Of The Army | Skin-active adjuvants for transcutaneous immunization |
EP1071377A1 (en) * | 1998-04-14 | 2001-01-31 | Merck & Co., Inc. | Needleless administration of polynucleotide formulations |
DE69941545D1 (en) * | 1998-11-04 | 2009-11-26 | Isis Innovation | TUBERCULOSIS DIAGNOSIS TEST |
US8197461B1 (en) | 1998-12-04 | 2012-06-12 | Durect Corporation | Controlled release system for delivering therapeutic agents into the inner ear |
US6465633B1 (en) | 1998-12-24 | 2002-10-15 | Corixa Corporation | Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis |
US7022320B1 (en) | 1999-02-09 | 2006-04-04 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis immunization |
JP4932086B2 (en) * | 1999-04-08 | 2012-05-16 | インターセル ユーエスエイ、インコーポレイテッド | Dry formulation for transcutaneous immunization |
AUPR074500A0 (en) * | 2000-10-13 | 2000-11-09 | Monash University | Treatment of t cell disorders |
US20050020524A1 (en) * | 1999-04-15 | 2005-01-27 | Monash University | Hematopoietic stem cell gene therapy |
US20040259803A1 (en) * | 1999-04-15 | 2004-12-23 | Monash University | Disease prevention by reactivation of the thymus |
US20040241842A1 (en) * | 1999-04-15 | 2004-12-02 | Monash University | Stimulation of thymus for vaccination development |
US20070274946A1 (en) * | 1999-04-15 | 2007-11-29 | Norwood Immunoloty, Ltd. | Tolerance to Graft Prior to Thymic Reactivation |
US20040265285A1 (en) * | 1999-04-15 | 2004-12-30 | Monash University | Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
US20040258672A1 (en) * | 1999-04-15 | 2004-12-23 | Monash University | Graft acceptance through manipulation of thymic regeneration |
WO2001000665A2 (en) * | 1999-06-28 | 2001-01-04 | Oklahoma Medical Research Foundation | Inhibitors of memapsin 2 and use thereof |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
EP1228237A1 (en) * | 1999-11-01 | 2002-08-07 | Chiron Corporation | Expression vectors, transfection systems, and method of use thereof |
CA2386341A1 (en) | 1999-11-18 | 2001-05-25 | Epimmune Inc. | Heteroclitic analogs and related methods |
US20020051791A1 (en) * | 1999-12-22 | 2002-05-02 | Galloway Darrel R. | Methods for protection against lethal infection with bacillus anthracis |
FR2804028B1 (en) * | 2000-01-21 | 2004-06-04 | Merial Sas | IMPROVED DNA VACCINES FOR PENSION ANIMALS |
US6552006B2 (en) | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
EP1259264A4 (en) * | 2000-02-23 | 2005-08-31 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
WO2001082964A1 (en) * | 2000-04-28 | 2001-11-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines |
US6590087B1 (en) * | 2000-05-25 | 2003-07-08 | Johns Hopkins University | whmD, an essential cell division gene from mycobacteria |
AU2001271963A1 (en) * | 2000-07-10 | 2002-01-21 | Colorado State University Research Foundation | Mid-life vaccine and methods for boosting anti-mycobacterial immunity |
JP2004511219A (en) | 2000-07-12 | 2004-04-15 | アジェンシス,インコーポレイテッド | Tumor antigens useful for diagnosis and treatment of bladder, ovarian, lung, and kidney cancer |
EP1313850B1 (en) | 2000-08-28 | 2008-08-06 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer |
US20060088512A1 (en) * | 2001-10-15 | 2006-04-27 | Monash University | Treatment of T cell disorders |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002064162A2 (en) * | 2001-02-13 | 2002-08-22 | Government Of The United States, As Represented By The Secretary Of The Army | Vaccine for transcutaneous immunization |
US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
EP1390075B1 (en) * | 2001-04-06 | 2012-01-18 | The University of Chicago | Chemotherapeutic induction of egr-1 promoter activity in gene therapy |
US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
WO2002083921A2 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
US7013940B2 (en) * | 2001-04-19 | 2006-03-21 | Michelin Recherche Et Technique S.A. | Device for attenuating cavity noise in a tire and wheel |
CA2448097A1 (en) | 2001-05-22 | 2002-11-28 | University Of Chicago | N4 virion single-stranded dna dependent rna polymerase |
US7604955B2 (en) * | 2001-08-13 | 2009-10-20 | Swey-Shen Alex Chen | Immunoglobulin E vaccines and methods of use thereof |
AU2002336446B2 (en) | 2001-09-06 | 2008-03-06 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
EP1450605B1 (en) | 2001-10-26 | 2011-12-07 | Baylor College Of Medicine | Composition to alter bone properties in a subject |
AU2002357143B2 (en) * | 2001-12-11 | 2009-07-30 | Advisys, Inc. | Growth hormone releasing hormone supplementation for treating chronically ill subjects |
KR20040099264A (en) * | 2002-01-18 | 2004-11-26 | 이노비오 에이에스 | Bispecific antibody dna constructs for intramuscular administration |
AU2003210818A1 (en) * | 2002-02-01 | 2003-09-02 | Cornell Research Foundation, Inc. | Compositions and methods for treatment of infectious and inflammatory diseases |
US20060009409A1 (en) * | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US20050267025A1 (en) * | 2002-02-01 | 2005-12-01 | Ho John L | Compositions and methods for treatment of infectious and inflammatory diseases |
EP1572902B1 (en) | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
ATE508188T1 (en) | 2002-02-01 | 2011-05-15 | Life Technologies Corp | OLIGONUCLEOTIDE COMPOSITIONS WITH IMPROVED EFFECTIVENESS |
EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
US20070037769A1 (en) * | 2003-03-14 | 2007-02-15 | Multicell Immunotherapeutics, Inc. | Compositions and methods to treat and control tumors by loading antigen presenting cells |
AU2003218181A1 (en) * | 2002-03-15 | 2003-09-29 | Multicell Immunotherapeutics, Inc. | Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response |
US7078037B2 (en) * | 2002-04-19 | 2006-07-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections |
WO2004041997A2 (en) * | 2002-05-01 | 2004-05-21 | National Institutes Of Health | Immunotherapy regimens in hiv-infected patients |
NZ537579A (en) | 2002-06-10 | 2006-10-27 | Vaccinex Inc | C35 peptide epitopes and their analogs |
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
CA2492160A1 (en) * | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US20090110702A1 (en) * | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
AU2003304195B8 (en) | 2002-07-15 | 2008-08-28 | Board Of Regents, The University Of Texas System | Combinatorial protein library screening by periplasmic expression |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
CN1754002B (en) | 2002-08-12 | 2010-09-08 | 杰能斯有限公司 | Compositions concerning poxviruses and cancer and its preparation method |
US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
ATE465753T1 (en) * | 2002-10-21 | 2010-05-15 | Eisai Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES CAUSED BY THE HUMAN PAPILLOMA VIRUS |
CA2503346C (en) | 2002-11-27 | 2014-03-18 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24p4c12 useful in treatment and detection of cancer |
EP1903056A3 (en) | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof |
JP2007524361A (en) | 2003-02-10 | 2007-08-30 | アジェンシス, インコーポレイテッド | 158P1D7 nucleic acid and corresponding protein useful for the treatment and detection of bladder cancer and other cancers |
US7262027B2 (en) * | 2003-03-14 | 2007-08-28 | Medical College Of Ohio | Polypeptide and DNA immunization against Coccidioides spp. infections |
AU2004225480A1 (en) * | 2003-03-26 | 2004-10-14 | Multicell Immunotherapeutics, Inc. | Selected RNA motifs to include cell death and/or apoptosis |
TW200424214A (en) * | 2003-04-21 | 2004-11-16 | Advisys Inc | Plasmid mediated GHRH supplementation for renal failures |
WO2004105681A2 (en) * | 2003-04-28 | 2004-12-09 | Innogenetics N.V. | Cd4+ human papillomavirus (hpv) epitopes |
DK1629088T3 (en) | 2003-05-30 | 2012-05-07 | Agensys Inc | VARIABLES OF THE PROSTATASTIC CELL ANTIGEN (PSCA) AND ITS SEQUENCES |
WO2004110482A1 (en) * | 2003-06-13 | 2004-12-23 | Isis Innovation Limited | Improved vaccines |
US20070224615A1 (en) * | 2003-07-09 | 2007-09-27 | Invitrogen Corporation | Methods for assaying protein-protein interactions |
CA2531698A1 (en) | 2003-07-09 | 2005-01-27 | Sentigen Biosciences, Inc. | Method for assaying protein-protein interaction |
NZ545364A (en) * | 2003-09-05 | 2009-06-26 | Genencor Int | HPV CD8+ T-cell epitopes |
US20080279812A1 (en) * | 2003-12-05 | 2008-11-13 | Norwood Immunology, Ltd. | Disease Prevention and Vaccination Prior to Thymic Reactivation |
EP1716173B8 (en) * | 2004-02-11 | 2012-06-27 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Carcinoembryonic antigen fusion protein and uses thereof |
CA2559586A1 (en) * | 2004-03-18 | 2005-09-29 | Fred Hutchinson Cancer Research Center | Methods and compositions involving s-ship promoter regions |
WO2005118864A2 (en) | 2004-05-28 | 2005-12-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
US20090221440A1 (en) * | 2004-07-12 | 2009-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions related to identifying protein-protein interactions |
WO2006135382A2 (en) | 2004-08-04 | 2006-12-21 | Chemocentryx, Inc. | Enzymatic activities in chemokine-mediated inflammation |
DK2302055T3 (en) | 2004-11-12 | 2014-10-13 | Asuragen Inc | Methods and compositions involving miRNA and miRNA inhibitor molecules |
NZ581306A (en) | 2004-11-16 | 2011-03-31 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
EP1817061B1 (en) * | 2004-12-01 | 2011-07-27 | Aeras Global Tuberculosis Vaccine Foundation | Electroporation of mycobacterium and overexpression of antigens in mycobacteria |
JP2008538894A (en) * | 2005-02-11 | 2008-11-13 | メルク エンド カムパニー インコーポレーテッド | Adenovirus serotype 26 vector, nucleic acid and virus produced thereby |
PL2325306T3 (en) | 2005-02-25 | 2014-07-31 | Oncotherapy Science Inc | Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides |
PL2289533T3 (en) | 2005-02-28 | 2014-02-28 | Oncotherapy Science Inc | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
NZ562453A (en) | 2005-03-31 | 2010-04-30 | Agensys Inc | Antibodies and related molecules that bind to 161P2F10B proteins |
DK1912675T3 (en) | 2005-07-25 | 2014-03-24 | Emergent Product Dev Seattle | B-cell reduction using specific and cd37-cd20-specific binding molecules |
KR20130087639A (en) | 2005-07-27 | 2013-08-06 | 온코세라피 사이언스 가부시키가이샤 | Colon cancer related gene tom34 |
WO2007021886A2 (en) * | 2005-08-10 | 2007-02-22 | Oklahoma Medical Research Foundation | Truncated memapsin 2 for use for treating alzheimer's disease |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
JP2009507853A (en) * | 2005-09-07 | 2009-02-26 | ジェンネレックス インコーポレイティッド | Systemic treatment of metastatic and / or systemic disseminated cancer using GM-CSF expressing poxvirus |
US7919258B2 (en) * | 2005-10-07 | 2011-04-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Rapid tuberculosis detection method |
EP2368570A3 (en) | 2006-01-18 | 2012-05-02 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
EP2441469A1 (en) * | 2006-03-14 | 2012-04-18 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
GB0605474D0 (en) * | 2006-03-17 | 2006-04-26 | Isis Innovation | Clinical correlates |
JP2009539413A (en) | 2006-06-12 | 2009-11-19 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Single-chain multivalent binding protein with effector function |
ATE543097T1 (en) | 2006-07-27 | 2012-02-15 | Univ Maryland | CELLULAR RECEPTOR FOR ANTIPROLIFERATIVE FACTOR |
US8481023B2 (en) | 2006-09-15 | 2013-07-09 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
WO2008047473A1 (en) | 2006-10-17 | 2008-04-24 | Oncotherapy Science, Inc. | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides |
WO2008130437A2 (en) | 2006-10-20 | 2008-10-30 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Modified cyanobacteria |
ATE555128T1 (en) | 2006-11-30 | 2012-05-15 | Res Dev Foundation | IMPROVED IMMUNOLOBULIN LIBRARIES |
TWI438207B (en) | 2007-02-21 | 2014-05-21 | Oncotherapy Science Inc | Peptide vaccines for cancers expressing tumor-associated antigens |
KR20080084528A (en) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | Oncolytic vaccinia virus cancer therapy |
TW201425333A (en) | 2007-04-11 | 2014-07-01 | Oncotherapy Science Inc | TEM8 peptides and vaccines comprising the same |
DK2155789T3 (en) | 2007-05-01 | 2013-10-21 | Res Dev Foundation | Immunoglobulin Fc libraries |
CN101990439A (en) * | 2007-07-06 | 2011-03-23 | 特鲁比昂药品公司 | Binding peptides having a c-terminally disposed specific binding domain |
EP2185190B1 (en) | 2007-08-31 | 2015-06-24 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
JP2011502484A (en) | 2007-11-01 | 2011-01-27 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | HLA-DR binding peptides and their use |
CA2711499C (en) | 2008-01-10 | 2018-09-25 | Research Development Foundation | Vaccines and diagnostics for the ehrlichioses |
US20110070601A1 (en) * | 2008-01-23 | 2011-03-24 | Rigshospitalet | Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40 |
HUE031940T2 (en) | 2008-01-25 | 2017-08-28 | Multivir Inc | P53 biomarkers |
CN102027105B (en) | 2008-03-17 | 2015-03-11 | 斯克里普斯研究所 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
WO2009117134A2 (en) * | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
ES2368700T3 (en) * | 2008-04-11 | 2011-11-21 | Emergent Product Development Seattle, Llc | IMMUNOTHERAPEUTIC AGENT FOR CD37 AND COMBINATION WITH A BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT OF THE SAME. |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
WO2009143167A2 (en) | 2008-05-19 | 2009-11-26 | Advaxis | Dual delivery system for heterologous antigens |
AU2009256202B2 (en) | 2008-06-04 | 2014-07-03 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of IPS cells using non-viral approach |
AU2009273128A1 (en) * | 2008-07-25 | 2010-03-11 | All India Institute Of Medical Science | Constructing a DNA chimera for vaccine development against Leishmaniasis and tuberculosis |
JP2012500005A (en) | 2008-08-12 | 2012-01-05 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | Method for generating iPS cells |
CA2734325A1 (en) | 2008-08-18 | 2010-02-25 | University Of Maryland, Baltimore | Derivatives of apf and methods of use |
EP2329044B1 (en) | 2008-08-27 | 2016-05-18 | Oncotherapy Science, Inc. | Prmt1 for target genes of cancer therapy and diagnosis |
JP2012504660A (en) | 2008-10-06 | 2012-02-23 | ユニバーシティ オブ シカゴ | Compositions and methods related to bacterial EAP, EMP and / or ADSA proteins |
WO2010048252A1 (en) * | 2008-10-23 | 2010-04-29 | Intervet International B.V. | Lawsonia intracellularis vaccines |
TWI539160B (en) | 2008-12-05 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Wdrpuh epitope peptides and vaccines containing the same |
EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
US8906677B2 (en) | 2008-12-17 | 2014-12-09 | The Scripps Research Institute | Generation and maintenance of stem cells |
EP2379720B1 (en) | 2009-01-20 | 2016-08-17 | Alona Zilberberg | Mir-21 promoter driven targeted cancer therapy |
TWI469791B (en) | 2009-02-18 | 2015-01-21 | Oncotherapy Science Inc | Foxm1 peptides and vaccines containing the same |
EP2408913B1 (en) | 2009-03-18 | 2016-12-14 | Oncotherapy Science, Inc. | Neil3 peptides and vaccines including the same |
EP3281947B1 (en) | 2009-04-03 | 2020-02-12 | The University of Chicago | Compositions and methods related to protein a (spa) variants |
WO2010129347A2 (en) | 2009-04-28 | 2010-11-11 | Vanderbilt University | Compositions and methods for the treatment of disorders involving epithelial cell apoptosis |
TWI507204B (en) | 2009-05-26 | 2015-11-11 | Oncotherapy Science Inc | Cdc45l peptides and vaccines including the same |
EP2548950B1 (en) | 2009-06-05 | 2017-10-25 | Cellular Dynamics International, Inc. | Reprogramming T cells and hematopoietic cells |
WO2011025826A1 (en) | 2009-08-26 | 2011-03-03 | Research Development Foundation | Methods for creating antibody libraries |
EP3409119B1 (en) | 2009-09-14 | 2020-08-12 | SillaJen Biotherapeutics, Inc. | Oncolytic vaccinia virus combination cancer therapy |
WO2011038290A2 (en) | 2009-09-25 | 2011-03-31 | The U. S. A., As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
AU2010300623A1 (en) * | 2009-09-30 | 2012-04-19 | Saint Louis University | Peptides for inducing heterosubtypic influenza T cell responses |
ES2938049T3 (en) | 2009-10-16 | 2023-04-04 | Scripps Research Inst | Induction of stem cells |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
BR112012013664B1 (en) | 2009-12-10 | 2020-11-10 | Turnstone Limited Partnership | oncolitic rhabdovirus |
TW201136604A (en) | 2009-12-14 | 2011-11-01 | Oncotherapy Science Inc | TMEM22 peptides and vaccines including the same |
US10080799B2 (en) | 2010-02-12 | 2018-09-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions related to glycoprotein-immunoglobulin fusions |
AU2011221227B2 (en) | 2010-02-25 | 2015-07-09 | Dana-Farber Cancer Institute, Inc. | BRAF mutations conferring resistance to BRAF inhibitors |
WO2011106705A2 (en) | 2010-02-26 | 2011-09-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Dna-protein vaccination protocols |
ES2631458T3 (en) | 2010-03-04 | 2017-08-31 | Interna Technologies B.V. | MRNA molecule defined by its source and its therapeutic uses in cancer associated with EMT |
CA2792910A1 (en) | 2010-03-11 | 2011-09-15 | Yusuke Nakamura | Hjurp peptides and vaccines including the same |
CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
TW201627003A (en) | 2010-04-02 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | ECT2 peptides and vaccines including the same |
US8808699B2 (en) | 2010-04-05 | 2014-08-19 | The University Of Chicago | Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response |
US9249195B2 (en) | 2010-04-07 | 2016-02-02 | Vanderbilt University | Reovirus vaccines and methods of use therefor |
CA2796601C (en) | 2010-04-19 | 2019-03-26 | Research Development Foundation | Rtef-1 variants and uses thereof |
ES2660239T3 (en) | 2010-06-09 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | A MEK1 mutation that confers resistance to RAF and MEK inhibitors |
ES2685171T3 (en) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramming cells to a new destination |
ES2670842T3 (en) | 2010-06-15 | 2018-06-01 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
CA2802087A1 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | A compendium of ready-built stem cell models for interrogation of biological response |
AU2011274367B2 (en) | 2010-07-02 | 2015-04-23 | The University Of Chicago | Compositions and methods related to protein A (SpA) variants |
CA2804599C (en) | 2010-07-06 | 2023-01-31 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
JP5897002B2 (en) | 2010-07-07 | 2016-04-13 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | Endothelial cell production by programming |
EP2601289B1 (en) | 2010-08-04 | 2017-07-12 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
WO2012034067A1 (en) | 2010-09-09 | 2012-03-15 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
CA2849382C (en) | 2010-09-22 | 2021-02-16 | The Regents Of The University Of Colorado, A Body Corporate | Therapeutic applications of smad7 for the treatment of oral mucositis |
WO2012138377A2 (en) | 2010-10-01 | 2012-10-11 | Trustees Of The University Of Pennsylvania | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
WO2012044979A2 (en) | 2010-10-01 | 2012-04-05 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Manipulation of stem cell function by p53 isoforms |
CN114164167A (en) | 2010-12-22 | 2022-03-11 | 菲特治疗公司 | Cell culture platform for single cell sorting and enhanced IPSC reprogramming |
CN103429258B (en) | 2011-01-04 | 2016-03-09 | 新罗杰公司 | By use oncolytic vaccinia virus generate for tumor antigen antibody and generate tumour-specific CDC |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
RU2539035C2 (en) * | 2011-01-13 | 2015-01-10 | Амир Закиевич Максютов | Preventive or therapeutic polyepitopic anti-tuberculosis vaccine construction providing induction of cellular immune response of cd4+ or cd8+ t-lymphocytes |
AU2012214643B2 (en) | 2011-02-07 | 2016-12-15 | Research Development Foundation | Engineered immunoglobulin Fc polypeptides |
WO2012109208A2 (en) | 2011-02-08 | 2012-08-16 | Cellular Dynamics International, Inc. | Hematopoietic precursor cell production by programming |
CN103687611A (en) | 2011-03-11 | 2014-03-26 | 阿德瓦希斯公司 | Listeria-based adjuvants |
EP3406628A1 (en) | 2011-04-08 | 2018-11-28 | Evaxion Biotech ApS | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
ES2931180T3 (en) | 2011-05-19 | 2022-12-27 | Fund Publica Andaluza Progreso Y Salud | Highly inducible dual promoter lentiviral Tet-on type system |
US9364532B2 (en) | 2011-06-08 | 2016-06-14 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
CA2841165A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
US9725490B2 (en) | 2011-07-29 | 2017-08-08 | Tokushima University | ERAP1-derived peptide and use thereof |
EP2742133B1 (en) | 2011-08-12 | 2017-10-04 | Oncotherapy Science, Inc. | Mphosph1 peptides and vaccines including the same |
US9556281B2 (en) | 2011-08-15 | 2017-01-31 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein A |
US20130101664A1 (en) | 2011-08-18 | 2013-04-25 | Donald W. Kufe | Muc1 ligand traps for use in treating cancers |
JP2013046596A (en) * | 2011-08-29 | 2013-03-07 | Alpha-Nano-Medica Co Ltd | New complex, medicine including the same and method of treatment for cancer |
WO2013053899A1 (en) | 2011-10-12 | 2013-04-18 | Moeller Niels Iversen | Peptides derived from campylobacter jejuni and their use in vaccination |
KR102020491B1 (en) | 2011-10-28 | 2019-09-10 | 온코세라피 사이언스 가부시키가이샤 | Topk peptides and vaccines including the same |
US10174314B2 (en) | 2011-12-22 | 2019-01-08 | Interna Technologies B.V. | MiRNA for treating head and neck cancer |
SG10201700392UA (en) | 2012-03-12 | 2017-03-30 | Advaxis Inc | Suppressor cell function inhibition following listeria vaccine treatment |
CN104703622B (en) | 2012-04-26 | 2017-05-24 | 芝加哥大学 | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease |
CN104768572B (en) | 2012-04-26 | 2021-08-24 | 芝加哥大学 | Staphylocoagulase antigens and methods of use thereof |
EP2872530A4 (en) | 2012-07-10 | 2016-04-06 | Oncotherapy Science Inc | Kif20a epitope peptides for th1 cells and vaccines containing the same |
US9644010B2 (en) | 2012-07-10 | 2017-05-09 | Oncotherapy Science, Inc. | LY6K epitope peptides for TH1 cells and vaccines containing the same |
PL2895600T3 (en) | 2012-09-11 | 2020-10-05 | Oncotherapy Science, Inc. | Ube2t peptides and vaccines containing the same |
EP2912058A1 (en) | 2012-10-23 | 2015-09-02 | The Board of Regents of The University of Texas System | Antibodies with engineered igg fc domains |
EP2917348A1 (en) | 2012-11-06 | 2015-09-16 | InteRNA Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
WO2014116721A1 (en) | 2013-01-22 | 2014-07-31 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Geminiviral vector for expression of rituximab |
WO2014130706A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
WO2014127478A1 (en) | 2013-02-21 | 2014-08-28 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Vaccine composition |
CN105229144A (en) | 2013-02-22 | 2016-01-06 | 细胞动力学国际有限公司 | By combination genetic engineering and chemical engineering via forward programming produce liver cell |
US10086093B2 (en) | 2013-02-28 | 2018-10-02 | The General Hospital Corporation | miRNA profiling compositions and methods of use |
US9422352B2 (en) | 2013-03-08 | 2016-08-23 | The Regents Of The University Of Colorado, A Body Corporate | PTD-SMAD7 therapeutics |
TWI658049B (en) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Kntc2 peptides and vaccines containing the same |
US9809801B2 (en) * | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
EP3421047B1 (en) | 2013-03-27 | 2021-05-05 | ImmunoVaccine Technologies Inc. | Method for improving the efficacy of a survivin vaccine in the treatment of cancer |
RU2520078C1 (en) * | 2013-04-25 | 2014-06-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) | METHOD FOR OBTAINING IMMUNOGENIC COMPOSITION BASED ON Ag85A-DBD HYBRID PROTEIN AND DEXTRANE; pAg85A-DBD RECOMBINANT PLASMIDE; Escherichia coli [pREP4, pAg85A-DBD] STRAIN; Ag85A-DBD CHIMERIC PROTEIN |
AU2014317861B2 (en) | 2013-09-09 | 2019-11-28 | Figene, Llc | Gene therapy for the regeneration of chondrocytes or cartilage type cells |
WO2015070009A2 (en) | 2013-11-08 | 2015-05-14 | The Board Of Regents Of The University Of Texas System | Vh4 antibodies against gray matter neuron and astrocyte |
WO2015070050A1 (en) | 2013-11-08 | 2015-05-14 | Baylor Research Institute | Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure |
WO2015082536A1 (en) | 2013-12-03 | 2015-06-11 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
JP6908381B2 (en) | 2014-01-29 | 2021-07-28 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Antibodies to MUC1-C / extracellular domain (MUC1-C / ECD) |
WO2015123561A2 (en) | 2014-02-14 | 2015-08-20 | University Of Utah Research Foundation | Methods and compositions for inhibiting retinopathy of prematurity |
EP3110836A1 (en) | 2014-02-25 | 2017-01-04 | Research Development Foundation | Sty peptides for inhibition of angiogenesis |
SG11201606934SA (en) | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
BR112017002212A2 (en) | 2014-08-04 | 2017-11-21 | Oncotherapy Science Inc | cdca1-derived peptide and vaccine containing the same |
CN106715461B (en) | 2014-08-04 | 2020-11-24 | 肿瘤疗法科学股份有限公司 | KOC 1-derived peptides and vaccines containing the same |
WO2016021510A1 (en) | 2014-08-04 | 2016-02-11 | オンコセラピー・サイエンス株式会社 | Urlc10-derived peptide and vaccine containing same |
US20180363070A9 (en) | 2014-08-12 | 2018-12-20 | Univ Wayne State | Systems and methods to detect stem cell stress and uses thereof |
WO2016075305A2 (en) | 2014-11-13 | 2016-05-19 | Evaxion Biotech Aps | Peptides derived from acinetobacter baumannii and their use in vaccination |
EP3242883A4 (en) | 2015-01-06 | 2018-10-17 | ImmunoVaccine Technologies Inc. | Lipid a mimics, methods of preparation, and uses thereof |
EP3244918A2 (en) | 2015-01-12 | 2017-11-22 | Evaxion Biotech ApS | Proteins and nucleic acids useful in vaccines targeting klebsiella pneumoniae |
EP3250675A1 (en) | 2015-01-28 | 2017-12-06 | SABIC Global Technologies B.V. | Methods and compositions for high-efficiency production of biofuel and/or biomass |
US10457737B2 (en) | 2015-02-09 | 2019-10-29 | Research Development Foundation | Engineered immunoglobulin Fc polypeptides displaying improved complement activation |
EP3259346A4 (en) | 2015-02-20 | 2018-07-11 | Baylor College of Medicine | P63 inactivation for the treatment of heart failure |
ES2959642T3 (en) | 2015-05-13 | 2024-02-27 | The Us Secretary Of The Department Of Health And Human Services | METHODS AND COMPOSITIONS TO INDUCE AN IMMUNE RESPONSE THROUGH CONSTRUCTIONS WITH CONSERVED ELEMENTS |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
EP4116316A1 (en) | 2015-07-04 | 2023-01-11 | Evaxion Biotech A/S | Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa |
WO2017040380A2 (en) | 2015-08-28 | 2017-03-09 | Research Development Foundation | Engineered antibody fc variants |
EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | Cd3 binding polypeptides |
JP6873482B2 (en) | 2015-10-08 | 2021-05-19 | オンコセラピー・サイエンス株式会社 | FOXM1-derived peptide and vaccine containing it |
CN117737124A (en) | 2015-10-16 | 2024-03-22 | 菲特治疗公司 | Platform for inducing and maintaining ground state pluripotency |
CA3002156A1 (en) | 2015-10-20 | 2017-04-27 | FUJIFILM Cellular Dynamics, Inc. | Multi-lineage hematopoietic precursor cell production by genetic programming |
JP6983771B2 (en) | 2015-10-30 | 2021-12-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | A method for producing T cells from stem cells and an immunotherapeutic method using the T cells. |
US11594135B2 (en) | 2015-11-02 | 2023-02-28 | Memgen, Inc. | Methods of CD40 activation and immune checkpoint blockade |
US20190038713A1 (en) | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
JP6987068B2 (en) | 2015-11-09 | 2021-12-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Glypican 2 as a cancer marker and therapeutic target |
US10946084B2 (en) | 2016-02-22 | 2021-03-16 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus |
EP3436049B1 (en) | 2016-03-31 | 2022-01-12 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
WO2017216384A1 (en) | 2016-06-17 | 2017-12-21 | Evaxion Biotech Aps | Vaccination targeting ichthyophthirius multifiliis |
CN109843321A (en) * | 2016-06-22 | 2019-06-04 | 国际艾滋病疫苗行动组织公司 | Recombined cytomegalovirus carrier as tuberculosis vaccine |
WO2017220787A1 (en) | 2016-06-24 | 2017-12-28 | Evaxion Biotech Aps | Vaccines against aearomonas salmonicida infection |
WO2018005975A1 (en) | 2016-07-01 | 2018-01-04 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
EP3889167A1 (en) | 2016-07-22 | 2021-10-06 | Evaxion Biotech ApS | Chimeric proteins for inducing immunity towards infection with s. aureus |
US9963498B2 (en) | 2016-08-18 | 2018-05-08 | Wisconsin Alumni Research Foundation | Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R |
WO2018067826A1 (en) | 2016-10-05 | 2018-04-12 | Cellular Dynamics International, Inc. | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
US20200263139A1 (en) | 2016-10-05 | 2020-08-20 | FUJIFILM Cellular Dynamics, Inc. | Methods for directed differentiation of pluripotent stem cells to hla homozygous immune cells |
WO2018111902A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
EP3565576A1 (en) | 2017-01-05 | 2019-11-13 | Evaxion Biotech ApS | Vaccines targeting pseudomonas aeruginosa |
WO2018195175A1 (en) | 2017-04-18 | 2018-10-25 | FUJIFILM Cellular Dynamics, Inc. | Antigen-specific immune effector cells |
US11497762B2 (en) | 2017-11-03 | 2022-11-15 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
WO2019099493A1 (en) | 2017-11-14 | 2019-05-23 | Henry Ford Health System | Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury |
EP3735467A4 (en) | 2018-01-05 | 2021-12-01 | Ottawa Hospital Research Institute | Modified vaccinia vectors |
WO2019145399A1 (en) | 2018-01-24 | 2019-08-01 | Evaxion Biotech Aps | Vaccines for prophylaxis of s. aureus infections |
EP3768698A4 (en) | 2018-03-19 | 2022-03-30 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
EP3775214A2 (en) | 2018-03-30 | 2021-02-17 | University of Geneva | Micro rna expression constructs and uses thereof |
TW202023581A (en) | 2018-08-02 | 2020-07-01 | 日商腫瘤療法 科學股份有限公司 | Cdca1-derived peptide and vaccine containing same |
JP7450945B2 (en) | 2018-08-30 | 2024-03-18 | テナヤ セラピューティクス, インコーポレイテッド | Cardiac cell reprogramming using myocardin and ASCL1 |
WO2020069313A2 (en) | 2018-09-28 | 2020-04-02 | Henry Ford Health System | Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke |
EP3870207A1 (en) | 2018-10-22 | 2021-09-01 | Evaxion Biotech ApS | Vaccines targeting m. catharrhalis |
WO2020111167A1 (en) | 2018-11-30 | 2020-06-04 | 国立大学法人徳島大学 | Therapeutic agent for breast caner comprising big3-phb2 interaction-inhibiting peptide derived from phb2 |
WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
US20220143168A1 (en) | 2019-02-27 | 2022-05-12 | Evaxion Biotech A/S | Vaccines targeting H. influenzae |
US20230137971A1 (en) | 2019-07-11 | 2023-05-04 | Tenaya Therapeutics Inc. | Cardiac cell reprogramming with micrornas and other factors |
EP3999546A1 (en) | 2019-07-19 | 2022-05-25 | The Children's Hospital of Philadelphia | Chimeric antigen receptors containing glypican 2 binding domains |
US20210147525A1 (en) | 2019-10-18 | 2021-05-20 | The Regents Of The University Of California | Methods and compositions for treating pathogenic blood vessel disorders |
KR102237349B1 (en) | 2019-10-23 | 2021-04-07 | 한국과학기술연구원 | Pharmaceutical composition for the treatment or prevention of nicotine addiction and withdrawal comprising miRNA |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
WO2021140123A1 (en) | 2020-01-06 | 2021-07-15 | Evaxion Biotech Aps | Vaccines targeting neisseria gonorrhoeae |
AU2021230476A1 (en) | 2020-03-02 | 2022-10-20 | Tenaya Therapeutics, Inc. | Gene vector control by cardiomyocyte-expressed microRNAs |
EP4127148A1 (en) | 2020-03-25 | 2023-02-08 | Erasmus University Rotterdam Medical Center | Reporter system for radionuclide imaging |
IL298558A (en) | 2020-05-27 | 2023-01-01 | Antion Biosciences Sa | Adapter molecules to re-direct car t cells to an antigen of interest |
AU2021280332A1 (en) | 2020-05-29 | 2022-12-01 | FUJIFILM Cellular Dynamics, Inc. | Bilayer of retinal pigmented epithelium and photoreceptors and use thereof |
JP2023528377A (en) | 2020-05-29 | 2023-07-04 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | Double cell aggregates of retinal pigment epithelium and photoreceptors and methods of use thereof |
WO2022053130A1 (en) | 2020-09-09 | 2022-03-17 | Sid Alex Group, S.R.O. | Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers |
CA3202849A1 (en) | 2021-02-09 | 2022-08-18 | University Of Houston System | Oncolytic virus for systemic delivery and enhanced anti-tumor activities |
EP4294445A1 (en) | 2021-02-19 | 2023-12-27 | Pfizer Inc. | Methods of protecting rna |
AU2022270611A1 (en) | 2021-05-03 | 2023-10-12 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
CN117716020A (en) | 2021-05-07 | 2024-03-15 | 安斯泰来再生医药协会 | Method for producing mature hepatocytes |
AU2022280051A1 (en) | 2021-05-26 | 2023-11-23 | FUJIFILM Cellular Dynamics, Inc. | Methods to prevent rapid silencing of genes in pluripotent stem cells |
CN117915944A (en) | 2021-07-05 | 2024-04-19 | 伊沃逊生物科技股份公司 | Vaccine targeting neisseria gonorrhoeae |
WO2023089556A1 (en) | 2021-11-22 | 2023-05-25 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
WO2023144779A1 (en) | 2022-01-28 | 2023-08-03 | Pfizer Inc. | Coronavirus antigen variants |
US20230295661A1 (en) | 2022-03-16 | 2023-09-21 | University Of Houston System | Persistent hsv gene delivery system |
GB202205265D0 (en) | 2022-04-11 | 2022-05-25 | Mogrify Ltd | Cell conversion |
GB202206507D0 (en) | 2022-05-04 | 2022-06-15 | Antion Biosciences Sa | Expression construct |
WO2023213393A1 (en) | 2022-05-04 | 2023-11-09 | Evaxion Biotech A/S | Staphylococcal protein variants and truncates |
WO2023239940A1 (en) | 2022-06-10 | 2023-12-14 | Research Development Foundation | Engineered fcriib selective igg1 fc variants and uses thereof |
WO2024006911A1 (en) | 2022-06-29 | 2024-01-04 | FUJIFILM Holdings America Corporation | Ipsc-derived astrocytes and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021797A1 (en) * | 1993-03-18 | 1994-09-29 | Merck & Co., Inc. | Nucleic acid pharmaceuticals |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591632A (en) * | 1987-03-02 | 1997-01-07 | Beth Israel Hospital | Recombinant BCG |
US5807830A (en) * | 1987-12-30 | 1998-09-15 | Cytoven J.V. | Method for treatment of purulent inflammatory diseases |
ES2200016T3 (en) * | 1989-03-21 | 2004-03-01 | Vical Incorporated | EXPRESSION OF EXECUTIVE POLINUCLEOTIDIC SEQUENCES IN A VERTEBRATE. |
ATE189684T1 (en) * | 1989-09-19 | 2000-02-15 | Innogenetics Nv | RECOMBINANT POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS CODING THEREFOR AND THEIR USE IN TUBERCULOSIS DIAGNOSIS |
EP0499003A1 (en) * | 1991-02-14 | 1992-08-19 | N.V. Innogenetics S.A. | Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5955077A (en) * | 1993-07-02 | 1999-09-21 | Statens Seruminstitut | Tuberculosis vaccine |
IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide vaccne for papillomavirus |
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
AU6280596A (en) * | 1995-06-15 | 1997-01-15 | University Of Victoria Innovation And Development Corporation | Mycobacterium tuberculosis dna sequences encoding immunostimlatory peptides |
US6160093A (en) * | 1996-08-29 | 2000-12-12 | Genesis Researth And Development Corporation Limited | Compounds and methods for treatment and diagnosis of mycobacterial infections |
-
1994
- 1994-11-14 US US08/338,992 patent/US5736524A/en not_active Expired - Fee Related
-
1995
- 1995-11-06 IL IL11588395A patent/IL115883A0/en unknown
- 1995-11-13 DK DK95939161T patent/DK0792358T3/en active
- 1995-11-13 NZ NZ296477A patent/NZ296477A/en not_active IP Right Cessation
- 1995-11-13 ZA ZA959608A patent/ZA959608B/en unknown
- 1995-11-13 WO PCT/US1995/014899 patent/WO1996015241A2/en not_active Application Discontinuation
- 1995-11-13 PL PL95320091A patent/PL184839B1/en not_active IP Right Cessation
- 1995-11-13 EP EP95939161A patent/EP0792358B1/en not_active Expired - Lifetime
- 1995-11-13 JP JP51633096A patent/JP3881014B2/en not_active Expired - Fee Related
- 1995-11-13 RU RU97110087/13A patent/RU2186109C2/en not_active IP Right Cessation
- 1995-11-13 SK SK597-97A patent/SK283254B6/en not_active IP Right Cessation
- 1995-11-13 PT PT95939161T patent/PT792358E/en unknown
- 1995-11-13 DE DE69534250T patent/DE69534250T2/en not_active Expired - Fee Related
- 1995-11-13 HU HU9701841A patent/HU222369B1/en not_active IP Right Cessation
- 1995-11-13 AT AT95939161T patent/ATE296882T1/en not_active IP Right Cessation
- 1995-11-13 ES ES95939161T patent/ES2242193T3/en not_active Expired - Lifetime
- 1995-11-13 KR KR1019970703204A patent/KR970707281A/en not_active Application Discontinuation
- 1995-11-13 AU AU41102/96A patent/AU715067B2/en not_active Ceased
- 1995-11-13 CZ CZ19971451A patent/CZ289383B6/en not_active IP Right Cessation
- 1995-11-13 CN CN95197250A patent/CN1171814A/en active Pending
-
1997
- 1997-05-13 NO NO972196A patent/NO972196L/en not_active Application Discontinuation
- 1997-05-13 FI FI972034A patent/FI972034A/en not_active IP Right Cessation
- 1997-05-14 MX MX9703606A patent/MX9703606A/en not_active IP Right Cessation
-
1998
- 1998-01-22 US US09/010,733 patent/US6384018B1/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021797A1 (en) * | 1993-03-18 | 1994-09-29 | Merck & Co., Inc. | Nucleic acid pharmaceuticals |
Non-Patent Citations (9)
Title |
---|
9th International Congress of Immunology, July 23-29, 1995, San Francisco, California, abstract 4843 * |
E.F. FYNAN ET AL.: "DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA., vol. 90, 1993, pages 11478 - 11482, XP002012390 * |
J. CONTENT ET AL.: "The genes coding for the antigen 85 complexes of Mycobacterium tuberculosis and Mycobnacterium bovis BCG are members of a gene family: cloning, sequence determination and genomic organization of the gene coding for antigen 85-C of mycobacterium tuberculosis", INFECTION AND IMMUNITY, vol. 59, no. 9, 1991, pages 3205 - 3212, XP002012386 * |
J. DE BRUYN ET AL.: "The 32 kDa protein antigen of M. bovis BCG and M. tuberculosis H37Rv*see the whole article*", TROPICAL MEDICINE AND PARASITOLOGY, vol. 41, 1990, pages 331 - 332, XP002012389 * |
J.R HAYNES ET AL: "Gene-gun-mediated DNA immunization elicits humoral, cytotoxic and protective immune responses", VACCINES, vol. 94, 1994, pages 65 - 70, XP002012392 * |
J.R. HAYNES ET AL.: "Accell Particle-mediated DNA immunization elicits humoral, cytotoxic and protective immune responses", AIDS RESEARCH AND HUMAN RETROVIRUS, vol. 10, no. Suppl. 2, 1994, pages S43 - S45, XP002012391 * |
LEILA DE MENDONCA LIMA: "Cloning and characterisation of the genes coding for the 85-complex antigens of mycobacterium leprae", INTERNATIONAL JOURNAL OF LEPROSY, vol. 61, no. 4, 1993, pages 108A, XP002012385 * |
LUK DE WIT ET AL.: "Nucleotide sequence of the 32 hDa-protein gene (antigen 85 A) of mycobacterium bovis BCG", NUCLEIC ACIDS RESEARCH, vol. 18, no. 13, 1990, pages 3995, XP002012387 * |
M. BORREMANS ET AL.: "Cloning, sequence determination nand expression of a 32 kDa-protein gene of Mycobacterium tuberculosis", INFECTION AND IMMUNITY, vol. 57, no. 10, 1989, pages 3123 - 3130, XP002012388 * |
Also Published As
Publication number | Publication date |
---|---|
FI972034A0 (en) | 1997-05-13 |
US6384018B1 (en) | 2002-05-07 |
PL184839B1 (en) | 2002-12-31 |
RU2186109C2 (en) | 2002-07-27 |
CZ145197A3 (en) | 1997-10-15 |
CN1171814A (en) | 1998-01-28 |
SK59797A3 (en) | 1998-01-14 |
JP3881014B2 (en) | 2007-02-14 |
AU4110296A (en) | 1996-06-06 |
NO972196D0 (en) | 1997-05-13 |
PT792358E (en) | 2005-09-30 |
IL115883A0 (en) | 1996-01-31 |
DE69534250T2 (en) | 2006-05-04 |
JPH10508753A (en) | 1998-09-02 |
EP0792358A2 (en) | 1997-09-03 |
AU715067B2 (en) | 2000-01-13 |
ZA959608B (en) | 1996-05-29 |
US5736524A (en) | 1998-04-07 |
NO972196L (en) | 1997-07-11 |
ES2242193T3 (en) | 2005-11-01 |
ATE296882T1 (en) | 2005-06-15 |
NZ296477A (en) | 1999-04-29 |
DK0792358T3 (en) | 2005-08-29 |
HUT77028A (en) | 1998-03-02 |
MX9703606A (en) | 1998-07-31 |
EP0792358B1 (en) | 2005-06-01 |
US20020032162A1 (en) | 2002-03-14 |
CZ289383B6 (en) | 2002-01-16 |
KR970707281A (en) | 1997-12-01 |
HU222369B1 (en) | 2003-06-28 |
WO1996015241A2 (en) | 1996-05-23 |
SK283254B6 (en) | 2003-04-01 |
DE69534250D1 (en) | 2005-07-07 |
FI972034A (en) | 1997-07-11 |
PL320091A1 (en) | 1997-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996015241A3 (en) | A polynucleotide tuberculosis vaccine | |
Saxena et al. | Pre-existing immunity against vaccine vectors–friend or foe? | |
Reed et al. | Prospects for a better vaccine against tuberculosis | |
Bastos et al. | Recombinant mycobacterium bovis BCG | |
EP1523331B1 (en) | Therapeutic tb vaccine | |
Skinner et al. | A DNA prime‐live vaccine boost strategy in mice can augment IFN‐γ responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis | |
Huygen | On the use of DNA vaccines for the prophylaxis of mycobacterial diseases | |
CA2132836A1 (en) | Immunization by inoculation of dna transcription unit | |
DE69434021D1 (en) | TUBERCULOSIS VACCINE | |
Triccas et al. | Comparative affects of plasmid‐encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis | |
Wedlock et al. | Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone | |
Branger et al. | Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge | |
Bumann | Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4+-T-cell responses | |
Al-Mariri | Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein | |
Palomares-Resendiz et al. | Immunogenic response of Brucella canis virB 10 and virB 11 mutants in a murine model | |
Golshani et al. | Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice | |
Young et al. | Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid‐encoded cytokines against Mycobacterium bovis | |
CA2205175A1 (en) | A polynucleotide tuberculosis vaccine | |
Ohara et al. | Protective responses against experimental Mycobacterium leprae infection in mice induced by recombinant Bacillus Calmette-Guerin over-producing three putative protective antigen candidates | |
Huygen | DNA vaccines against mycobacterial diseases | |
Vordermeier et al. | Development of cattle TB vaccines in the UK | |
Dietrich et al. | Novel vaccination strategies based on recombinant Mycobacterium bovis BCG | |
AU3980497A (en) | A vector for polynucleotide vaccines | |
NEUPANEēē et al. | Immunoprophylaxis against Mycobacterium leprae infection with subunit vaccines | |
CN101428143B (en) | Attenuated bacteria vector tuberculosis vaccine carrying tuberculosis gene, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95197250.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 296477 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2205175 Country of ref document: CA Ref document number: 2205175 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995939161 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 59797 Country of ref document: SK Ref document number: PV1997-1451 Country of ref document: CZ Ref document number: 1019970703204 Country of ref document: KR Ref document number: 972034 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1995939161 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-1451 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970703204 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-1451 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995939161 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970703204 Country of ref document: KR |